Pharmaceutically acceptable salt of a substituted fused heteroaromatic pyrrolidinone

Abstract

Disclosed is a pharmaceutically acceptable salt of a compound of Formula 1, wherein G, L1, L2, R1, R2, R3, and R4 are as defined in the specification. This disclosure also relates to a method for preparing the pharmaceutically acceptable salt of a compound of Formula 1, to a pharmaceutical composition which contains it, and to treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.